{"filings":[{"id":184103,"accession_number":"0001683168-25-000009","cik":836564,"company_name":"Mosaic ImmunoEngineering Inc.","ticker":"CPMV","form_type":"8-K","filed_at":"2025-01-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Mosaic ImmunoEngineering extends Oncotelic acquisition term sheet to June 30, 2025","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Binding term sheet for acquisition of Oncotelic's necroptosis cancer therapies and AI tech extended to June 30, 2025.","Original deal: $15M stock issuance at closing plus up to $15M milestone shares.","Extension allows more time for due diligence and drafting definitive agreements; no guarantee a deal will close.","Parties continue negotiating; prior expiration was December 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":5326592.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216711,"accession_number":"0001683168-24-005057","cik":836564,"company_name":"Mosaic ImmunoEngineering Inc.","ticker":"CPMV","form_type":"8-K","filed_at":"2024-07-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Carlton Johnson resigns from Mosaic ImmunoEngineering board, effective July 23, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Carlton Johnson notified the Board of his resignation effective immediately on July 23, 2024.","He also resigned from all Board committees, including Audit and Compensation Committees.","Resignation is not due to any disagreement with the company regarding operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5326592.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236390,"accession_number":"0001683168-24-003923","cik":836564,"company_name":"Mosaic ImmunoEngineering Inc.","ticker":"CPMV","form_type":"8-K","filed_at":"2024-05-31T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Mosaic ImmunoEngineering CFO Paul Lytle moves to part-time, pay cut to $1,600/month","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Paul Lytle reduced to part-time effective June 1, 2024, max 8 hours/month, monthly rate $1,600.","All deferred unpaid compensation to be paid upon completion of a capital raise of at least $4M.","Company will grant RSUs equal to 20% of deferred salary on closing date of the capital raise.","Lytle no longer eligible for PTO or group insurance benefits under the revised arrangement.","Agreement reflects cost-containment efforts amid need for new funding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5326592.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236389,"accession_number":"0001683168-24-003732","cik":836564,"company_name":"Mosaic ImmunoEngineering Inc.","ticker":"CPMV","form_type":"8-K","filed_at":"2024-05-21T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Mosaic ImmunoEngineering changes auditor; KMJ resigns, Rose Snyder & Jacobs appointed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["KMJ Corbin & Company resigned on May 21, 2024, after its partners joined Crowe LLP.","No adverse opinions or disagreements in fiscal years 2022 and 2023; going concern paragraph noted.","New auditor Rose, Snyder & Jacobs LLP engaged on May 22, 2024.","No reportable events or consultations with the new auditor prior to engagement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5326592.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236388,"accession_number":"0001683168-24-002761","cik":836564,"company_name":"Mosaic ImmunoEngineering Inc.","ticker":"CPMV","form_type":"8-K","filed_at":"2024-04-29T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Mosaic to acquire Oncotelic's clinical necroptosis cancer assets for up to $30M in stock","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Binding term sheet signed April 26, 2024; acquisition includes VDA necroptosis therapies and AI platform.","Initial $15M in common or preferred stock; milestone payments up to $15M more in shares.","Oncotelic to provide operational loan through June 1 and assist in raising $2M initial funding.","If funding fails, transaction may convert to reverse acquisition/merger; shareholder approval required.","Mosaic gains regulatory packages and access to Oncotelic's AI for immunotherapy combination discovery."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5326592.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236387,"accession_number":"0001683168-24-002534","cik":836564,"company_name":"Mosaic ImmunoEngineering Inc.","ticker":"CPMV","form_type":"8-K","filed_at":"2024-04-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Mosaic ImmunoEngineering announces passing of director Gloria Felcyn","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Director Gloria Felcyn died on April 17, 2024.","She had served as an independent director on the Board since 2002.","Felcyn was a member of the Audit, Compensation, and Corporate Governance and Nominating Committees.","No replacement director has been announced at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5326592.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254047,"accession_number":"0001683168-24-001813","cik":836564,"company_name":"Mosaic ImmunoEngineering Inc.","ticker":"CPMV","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["1.01","1.02"],"status":"ready","headline":"CWRU terminates Mosaic's CPMV license for lead candidate MIE-101 over ~$407K unpaid IP fees","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Effective March 22, 2024, CWRU terminated the exclusive worldwide license agreement due to financial default.","Amount owed to CWRU increased to approximately $407,000 as of Dec. 31, 2023; company lacks capital to pay.","Company evaluating strategic options including additional capital, M&A, or possible wind-down/liquidation.","License was for foundational technology (CPMV) behind MIE-101, the sole immunotherapy candidate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5326592.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":308877,"accession_number":"0001683168-23-004424","cik":836564,"company_name":"Mosaic ImmunoEngineering Inc.","ticker":"CPMV","form_type":"8-K","filed_at":"2023-06-26T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Mosaic ImmunoEngineering receives $300k for preferred shares; stock moving to OTC Pink","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Redeemed remaining 910k Series A Preferred shares for $300k lump sum ($0.33/share), received June 22, 2023.","Board decided not to pay OTCQB semi-annual fees due June 30, 2023; stock will be quoted on OTC Pink from July 3, 2023.","Move to OTC Pink may adversely affect liquidity; company may not requalify for OTCQB."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5326592.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":308876,"accession_number":"0001683168-23-002890","cik":836564,"company_name":"Mosaic ImmunoEngineering Inc.","ticker":"CPMV","form_type":"8-K","filed_at":"2023-05-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director and acting Chief Scientific Officer Nicole Steinmetz resigns, will remain as scientific advisor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Nicole Steinmetz, Ph.D., resigned as director and acting CSO effective May 2, 2023.","Resignation not due to disagreement with company on operations, policies, or practices.","She will continue to serve as a scientific advisor to the Company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5326592.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":361798,"accession_number":"0001683168-22-004893","cik":836564,"company_name":"Mosaic ImmunoEngineering Inc.","ticker":"CPMV","form_type":"8-K","filed_at":"2022-07-12T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Mosaic enters redemption agreement for $840K in Series A Preferred; initial $336K received","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Holocom to redeem 2.1M Series A Preferred shares for $840K total; initial payment of $336K due July 11, 2022.","Monthly payments of $14K-$21K over 30 months beginning August 2022; expedited redemption if excess cash.","Late payments accrue 8% interest, retroactive to 12% if unpaid after 90 days.","Mosaic retains two board seats at Holocom until full redemption; Holocom and SVI barred from distributions or bonuses until paid."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5326592.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":381225,"accession_number":"0001683168-22-003217","cik":836564,"company_name":"Mosaic ImmunoEngineering Inc.","ticker":"CPMV","form_type":"8-K","filed_at":"2022-05-05T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Mosaic ImmunoEngineering secures exclusive worldwide CPMV license from Case Western Reserve University","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Licensed technology covers cowpea mosaic virus (CPMV)-based oncology treatments for human and companion animal cancers.","Development milestone payments up to $1.8M per human product; tiered royalties starting in mid-single digits on net sales.","Annual minimum royalty of $10,000 starting year 2, rising based on net sales; CWRU to be reimbursed ~$278K in IP fees.","Agreement term runs 20 years or last patent expiry; Mosaic gains rights to core technology behind lead candidate MIE-101."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5326592.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":399241,"accession_number":"0001683168-22-001209","cik":836564,"company_name":"Mosaic ImmunoEngineering Inc.","ticker":"CPMV","form_type":"8-K","filed_at":"2022-02-22T23:59:59+00:00","items":["1.01","2.03","3.02","3.03","9.01"],"status":"ready","headline":"Mosaic ImmunoEngineering raises $342K via 8% convertible notes with board participation","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $342,632 principal of 8% convertible notes to 16 accredited investors; 5 board members invested $155,000 combined.","Proceeds of $341,632 for general purposes; notes have no maturity, 8% simple interest, convertible in future equity financing.","Conversion price: lesser of 80% of lowest per-share price in Qualified Financing (≥$5M) or $1.00; also convertible in smaller financings.","Upon corporate transaction, holders may elect 1.5x principal plus interest or conversion at $1.00 per share.","Amended May 2021 notes for certain purchasers: conversion price replaced with same formula (80% discount or $1.00)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":5326592.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}